ArticleAmerican journal of translational research2016
Influence of chronic kidney disease on the outcome of patients with chronic total occlusion.
Article in American journal of translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Myocardial revascularization in patients with chronic kidney disease: a systematic review and meta-analysis of surgical versus percutaneous coronary revascularization.Interdisciplinary cardiovascular and thoracic surgery · 2025Pooled it
- Impact of impaired renal function on outcomes of chronic total occlusion undergoing revascularization: a systemic review and meta-analysis.International urology and nephrology · 2022Pooled it
- Impact of CTO-related myocardial infarction and procedural success on long-term outcomes after CTO PCI.Frontiers in cardiovascular medicine · 2026Article
- Revascularization of coronary chronic total occlusion in patients with end stage renal disease.Scientific reports · 2025Article
- Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Renal Dysfunction.The American journal of cardiology · 2020Article
- Cystatin C-Based Renal Function in Predicting the Long-Term Outcomes of Chronic Total Occlusion After Percutaneous Coronary Intervention.Frontiers in cardiovascular medicine · 2020Article
- Incidence and in-hospital outcomes of single-vessel coronary chronic total occlusion treated with percutaneous coronary intervention.International journal of cardiology · 2018Observational
- Outcomes after percutaneous coronary intervention for chronic total occlusion according to baseline renal function.Clinical research in cardiology : official journal of the German Cardiac Society · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChronic kidney disease (CKD) predicted a poor prognosis in patients with coronary artery disease. There is a paucity of data on outcomes after revascularization in patients with chronic total occlusion (CTO) and CKD. This study aims to investigate the impact of CKD on the revascularization of CTO.
methodsThis study enrolled 1,092 CTO patients received treatments in our hospital between February 2009 and January 2014. Major adverse cardiac and cerebrovascular events (MACCE) and all-cause mortality were compared to evaluate medium- and long-term outcomes. Median follow-up was 39 months (interquartile range, 27-52 months).
resultCKD decreased cumulative MACCE-free survival rate (54.4 ± 6.2% vs. 70.9 ± 2.5%, P < 0.001) and cumulative survival rate (68.6 ± 6.3% vs. 90.5 ± 1.6%, P < 0.001). Revascularization was associated with better outcomes among patients with (MACCE-free survival rate: 64.8 ± 5.7% vs. 20.1 ± 15.3%, P = 0.009; survival rate 78.4 ± 5.6% vs. 38.7 ± 17.4%, P = 0.006) or without CKD (MACCE-free survival rate 73.9 ± 2.7% vs. 61.0 ± 5.4%, P = 0.001; survival rate 92.9 ± 1.5% vs. 83.8 ± 4.0%, P = 0.009). The benefit from revascularization was attenuated by CKD. Compared with percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) had similar cumulative survival rates among patients, whether with or without CKD, but was associated with a higher cumulative MACCE-free survival rate (80.5 ± 3.4% vs. 68.5 ± 4.0%, P = 0.017) among patients without CKD.
conclusionCKD attenuated the benefit from revascularization for CTO. Moreover, CABG was not superior to PCI among CTO patients, but with a reduction in MACCE in patients without CKD.
Indexed as
Identifiers
27069553PMC4759429W2422502103What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.